Latest Research And Development News

Objective Corporation Limited reported a solid 5% revenue increase to $123.5 million and a 13% rise in net profit after tax to $35.44 million for FY2025, alongside a strategic acquisition that broadens its e-planning software portfolio.

Codan Limited reported a robust FY25 with 22% revenue growth to $674.2 million and a 27% jump in net profit, driven by organic expansion and strategic acquisitions. The company’s communications and metal detection segments both posted solid gains, setting a confident tone for FY26.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial expansion and strategic investments in R&D and manufacturing. The company confirms full-year guidance while advancing key clinical trials and product launches.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

VEEM Limited’s FY25 results reveal a challenging year with revenue down 15%, yet a strong second half turnaround driven by cost cuts and efficiency gains. The company also secured a significant $65 million contract extension and new supplier status for a major US submarine program.

VEEM Ltd posted a 15% revenue decline and a 57% net profit drop for FY25, reflecting cyclical defence contract impacts. The company secured a $65 million ASC contract extension and continues investing in R&D and automation to drive future growth.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

VEEM Limited has achieved approved supplier status with Huntington Ingalls Newport News Shipbuilding, positioning itself to enter the US defence supply chain with anticipated RFQs in the first half of FY26.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.